UPDATE: Jefferies Starts Nuvation Bio Inc (NUVB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Wedbush Starts Nuvation Bio Inc (NUVB) at Outperform
March 8, 2021 6:29 AM ESTWedbush analyst David Nierengarten initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Outperform rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Nuvation Bio Inc... More
Cowen Starts Nuvation Bio Inc (NUVB) at Outperform
March 8, 2021 5:32 AM ESTCowen analyst Yaron Werber initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Outperform rating.
The analyst comments "Nuvations proven team is building a deep pipeline focusing on novel and validated oncogenic pathways. NUV-422, a CDK2/4/6 inhibitor, commenced Ph1 in Dec. 20 for... More
UPDATE: BMO Capital Starts Nuvation Bio Inc (NUVB) at Outperform
March 8, 2021 3:02 AM EST(Updated - March 8, 2021 4:31 AM EST)
BMO Capital analyst Do Kim initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Outperform rating and a price target of $16.00.
The analyst comments "We believe Nuvation's deep pipeline leverages clinically validated cancer targets and known... More
